Generic molecule: cabozantinib
Approval date: Nov. 29
The scoop: The multikinase inhibitor's approval to treat thyroid cancer made it the second drug approved to treat the medullary form of the disease in as many years; AstraZeneca's ($AZN) Calpresa was approved in November 2011. FierceBiotech featured cabozantinib as one of the top 10 cancer drugs in late-stage development earlier this year. Exelixis ($EXEL) has been looking for approval for the much larger prostate cancer market, but the drug in still in Phase III trials to treat the castrate-resistant form of the disease.